Elixinol Wellness delivered a standout Q4 FY24 performance with a 71% jump in cash receipts and a 64% rise in revenue, driven by key acquisitions and operational efficiencies. The company edges closer to EBITDA break-even, setting the stage for growth in 2025.
Qoria Limited reports robust December quarter results for FY2025, driven by strong ARR growth, expanding global reach, and strategic AI innovations that promise to accelerate future growth.